Fig. 3
Impact of extramedullary manifestations on survival in acute myeloid leukemia. For the comparison between both clinically and histologically determined EM AML and non EM-AML, both event-free (A) and relapse-free survival (B) did not differ significantly while overall survival (C) was significantly reduced. When we focused only on histologically confirmed EM AML (n = 38) excluding cases for whom only clinical diagnosis of EM AML was available, we found that both event-free survival (D) as well as overall survival (F) were significantly reduced compared to AML patients without EM while relapse-free survival did not differ (E). Significance was determined at α = 0.05; * p < 0.05, ** p < 0.01, ***p < 0.001; EM AMLh+c = histologically and clinically diagnosed cases of EM AML (panel A–C); EML AMLh = only histologically confirmed cases of EM AML (panel D–F)